W/ #brexafemme recall spent last few days trying to get compounded topical antifungal for patient w/resistant genital #Glabrata (failed boric). Futile waste of time. anyone used #Nystatin oint (no vaginal suppositories in 🇺🇸?) vaginally?
I’m close to using much more costly micafungin infusion.
I’m close to using much more costly micafungin infusion.
January 3, 2025 at 4:58 PM
W/ #brexafemme recall spent last few days trying to get compounded topical antifungal for patient w/resistant genital #Glabrata (failed boric). Futile waste of time. anyone used #Nystatin oint (no vaginal suppositories in 🇺🇸?) vaginally?
I’m close to using much more costly micafungin infusion.
I’m close to using much more costly micafungin infusion.
@mcuban.bsky.social
Looking for a better price for Brexafemme. Antifungal. Best rate we can find is about $500 for one course. No insurance touches it yet. Would love any guidance ❤️
Looking for a better price for Brexafemme. Antifungal. Best rate we can find is about $500 for one course. No insurance touches it yet. Would love any guidance ❤️
January 3, 2025 at 2:40 AM
@mcuban.bsky.social
Looking for a better price for Brexafemme. Antifungal. Best rate we can find is about $500 for one course. No insurance touches it yet. Would love any guidance ❤️
Looking for a better price for Brexafemme. Antifungal. Best rate we can find is about $500 for one course. No insurance touches it yet. Would love any guidance ❤️
#SCYX SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/SCYX/scynexis-reports-first-quarter-2025-financial-results-and-provides-1rsi4nv9vpc3.html
https://www.stocktitan.net/news/SCYX/scynexis-reports-first-quarter-2025-financial-results-and-provides-1rsi4nv9vpc3.html
SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
SCYNEXIS (NASDAQ: SCYX) reported Q1 2025 financial results and key developments. The FDA lifted the clinical hold on ibrexafungerp, but SCYNEXIS faces a disagreement with GSK regarding the restart of the Phase 3 MARIO study for invasive candidiasis treatment. GSK maintains commitment to Brexafemme commercialization. In China, Hansoh received NMPA approval for ibrexafungerp in acute VVC treatment, triggering future milestone payments and ~10% royalties. The company presented positive preclinical data for SCY-247, its second-generation fungerp candidate, with Phase 1 results expected in Q3 2025. Financial highlights include: Q1 net loss of $5.4 million ($0.11 per share), revenue of $0.3 million, and cash position of $53.8 million providing runway into Q3 2026.
www.stocktitan.net
May 15, 2025 at 8:20 PM
#SCYX SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/SCYX/scynexis-reports-first-quarter-2025-financial-results-and-provides-1rsi4nv9vpc3.html
https://www.stocktitan.net/news/SCYX/scynexis-reports-first-quarter-2025-financial-results-and-provides-1rsi4nv9vpc3.html